What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
The scientist’s investigation covers issues in Cancer research, Internal medicine, Lung cancer, Cancer and Breast cancer.
His study in Cancer research is interdisciplinary in nature, drawing from both Immunohistochemistry, Reverse transcription polymerase chain reaction, Gene expression, DNA methylation and Carcinogenesis.
Yoshitaka Fujii has included themes like Gastroenterology, Endocrinology, microRNA and Oncology in his Internal medicine study.
His Lung cancer study combines topics from a wide range of disciplines, such as Carcinoma, Surgery and Adenocarcinoma.
As a part of the same scientific study, Yoshitaka Fujii usually deals with the Cancer, concentrating on Pathology and frequently concerns with Oncogene, Cell, Molecular medicine, CD8 and Esophageal disease.
As a member of one scientific family, Yoshitaka Fujii mostly works in the field of Gefitinib, focusing on Insertion and, on occasion, Epidermal growth factor receptor.
His most cited work include:
- EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. (7935 citations)
- Characterizing the cancer genome in lung adenocarcinoma (937 citations)
- Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. (303 citations)
What are the main themes of his work throughout his whole career to date?
Yoshitaka Fujii focuses on Cancer research, Internal medicine, Lung cancer, Pathology and Cancer.
His studies examine the connections between Cancer research and genetics, as well as such issues in Gene expression, with regards to Messenger RNA, Metastasis and Molecular biology.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Endocrinology and Oncology.
His biological study spans a wide range of topics, including Surgery, Epidermal growth factor receptor, Carcinoma, Lung and Adenocarcinoma.
His research in Epidermal growth factor receptor is mostly focused on Gefitinib.
His studies in Pathology integrate themes in fields like Respiratory disease, Cell and Esophageal cancer.
He most often published in these fields:
- Cancer research (37.15%)
- Internal medicine (31.58%)
- Lung cancer (31.27%)
What were the highlights of his more recent work (between 2011-2017)?
- Lung cancer (31.27%)
- Cancer research (37.15%)
- Surgery (19.20%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Lung cancer, Cancer research, Surgery, Internal medicine and Cancer.
His research in Lung cancer intersects with topics in Carcinoma, Oncogene, Survival rate and Adenocarcinoma.
Yoshitaka Fujii has researched Cancer research in several fields, including Immunohistochemistry, Epidermal growth factor receptor, Mutation, KRAS and Metastasis.
His Surgery study integrates concerns from other disciplines, such as Idiopathic pulmonary fibrosis and Pneumonectomy.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Endocrinology, Single-nucleotide polymorphism and Oncology.
His research integrates issues of Tyrosine-kinase inhibitor and Gefitinib in his study of Proportional hazards model.
Between 2011 and 2017, his most popular works were:
- Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer (150 citations)
- High Expression of MicroRNA-210 is an Independent Factor Indicating a Poor Prognosis in Japanese Triple-negative Breast Cancer Patients (63 citations)
- KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. (48 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
His main research concerns Lung cancer, Cancer research, Adenocarcinoma, Pathology and Surgery.
His Lung cancer study deals with the bigger picture of Internal medicine.
His Cancer research study integrates concerns from other disciplines, such as Immunohistochemistry and Cancer.
His work deals with themes such as Breast cancer, Estrogen receptor and microRNA, which intersect with Immunohistochemistry.
His research in Pathology intersects with topics in Myasthenia gravis and Chemotherapy.
His Surgery research is multidisciplinary, incorporating perspectives in Exacerbation, Non small cell, Pneumonectomy and Usual interstitial pneumonia.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
